← Stock Trading Canary · All insider profiles
INSIDER PROFILE · DE
Prisca Anand
Management Board Member (Vorstand) · Initial notification
Profile key: de|prisca anand
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 2
- Purchases · 24M
- 2
- Average purchase
- —
- Gross purchase value
- —
- Last purchase
- 2026-08-11
- Completed 20D events
- 2.0
- Outcome status
- INSUFFICIENT_SAMPLE
Latest company: Newron Pharmaceuticals S.p.A.
Companies: Newron Pharmaceuticals S.p.A.
Post-purchase outcomes
Benchmark-relative outcomes are available against DAX.
- Excess return = stock return − DAX return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small sample | 100.0% (2/2) | 100.0% (2/2) | +11.5% | +11.5% | +11.5% |
| 20D | 2Small sample | 100.0% (2/2) | 100.0% (2/2) | +3.9% | +3.9% | +3.9% |
| 60D | 0No data | Awaiting maturity | — | — | — | — |
| 120D | 0No data | Awaiting maturity | — | — | — | — |
Research patterns
- First purchase in 12M
- 2/2
- Large purchase ≥ €100k
- Not classifiable
- Cluster buying · 15D
- 2/2
- Buying the dip · ≥20% below prior 52W high
- 2/2
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.